Upgrade to SI Premium - Free Trial

Bristol-Myers Squibb (BMY) Weakness Unwarranted - JPMorgan

October 26, 2017 1:04 PM
JPMorgan maintains Overweight on Bristol-Myers Squibb Co. (NYSE: BMY).Analyst Chris Schott says the overall results for Q3 were solid ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments

Next Articles